Diaceutics (LSE:DXRX), the diagnostics data and commercialisation services group, has spent the autumn of 2026 building on a solid set of half-year figures. Its interim results for the six months to 30 June 2026, published on 22 September, showed annual Recurring Revenue up sharply, and the company has since expanded a key Partnership and held a Capital Markets webinar setting out its "Precision for All" strategy.

What the company does

Diaceutics works with pharmaceutical companies to help precision medicines reach the patients who can benefit from them. Precision medicines often depend on a diagnostic test to identify eligible patients, and Diaceutics supports this process through data, analytics and services that span diagnostic regulatory planning, analysis of the testing landscape and engagement with physicians. A central part of its offer is Relay, a multi-year partnership model under which it provides integrated commercialisation services to drug developers.

Latest developments

According to the interim results, annual recurring revenue rose 79% to £29.4 million, while revenue for the half reached £17.5 million, an increase of 22% on a constant currency basis. The order book grew 38% to £43.7 million. Gross Margin increased to 85% and the Business generated positive free Cash Flow of £0.7 million, a £3.1 million improvement on the prior-year period. The company also said that by August its visibility over median analyst consensus revenue forecasts for 2026 had risen to 107%, meaning contracted and expected revenue already exceeded the market's central estimate.

The results coincided with the launch of a market repositioning called Precision for All, which the company said significantly expands the range of therapies it can address. On 14 October 2026 Diaceutics announced a capital markets webinar under the same banner to explain the strategy to investors.

On 24 September 2026 the company announced an expanded Relay partnership with Syndax Pharmaceuticals, building on an agreement first signed in the fourth quarter of 2025. The expanded deal supports the commercialisation of a Syndax precision oncology medicine for acute leukaemia, with the aim of speeding up the identification and treatment of eligible patients. Financial terms were not disclosed. In August the company also launched a next-generation sequencing concordance study with a partner referred to as PCC.

More recently, in mid-November, the company reported several director and PDMR share dealings and a notification of a change in a major holding.

Financial and Dividend picture

The shift towards recurring revenue is the main feature of the half-year numbers, giving the group greater visibility than a model built on one-off projects. Diaceutics has not announced a dividend, and the interim statement focused on growth rather than Shareholder distributions.

Sector and index context

Diaceutics is one of the healthcare technology names in the FTSE AIM All Share Index. Its fortunes are linked to the pace of precision medicine launches, particularly in oncology, and to pharmaceutical companies' willingness to spend on launch support. Drug Development budgets can be cyclical.

Key risks

Revenue depends on a relatively concentrated set of pharmaceutical clients and on the success of the specific drugs it supports; regulatory delays or disappointing launches can reduce Demand for services. Currency movements matter because much of the business is international, as the use of constant currency figures shows. Delivering on the wider Precision for All ambition will require execution and continued investment.

What to watch next

Investors will look for full-year results to confirm whether revenue meets or beats consensus, as the August visibility suggested, and for further Relay partnership wins. Progress in converting the order book into revenue and maintaining positive free cash flow will also be closely followed.